高盛：上调百济神州目标价至408.79美元

Core Insights - Goldman Sachs reports that BeiGene's product sales in Q3 reached $1.4 billion, a 40% year-over-year increase, exceeding market expectations [2] - Brukinsa is the main growth driver, with revenue surpassing $1 billion for the first time, reflecting a 51% year-over-year growth and establishing it as the global leader in the BTK market, surpassing Imbruvica [2] - Due to strong sales performance, the company raised its full-year sales guidance to between $5.1 billion and $5.3 billion [2] - Goldman Sachs adjusted BeiGene's earnings per share forecasts for 2025 to 2027 and maintained a "Buy" rating, increasing the target price for U.S. stocks from $399.73 to $408.79 [2]